Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Alyson Haslam, Vinay Prasad
https://pubmed.ncbi.nlm.nih.gov/31050774/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2023-08-07
346
Participants Needed
1
Research Sites
65 weeks
Total Duration
Researchers are evaluating the use of sugemalimab as a consolidation therapy compared to a placebo in patients with limited-stage small cell lung cancer LS-SCLC who have not shown disease progression after completing concurrent or sequential chemoradiotherapy. This phase 23 randomized, double-blind, placebo-controlled study aims to assess the effectiveness of sugemalimab in this patient population, with progression-free survival as the primary outcome. Participants are randomly assigned in equal numbers to receive either sugemalimab or a placebo. Sugemalimab is given by intravenous infusion at a dose of 1200 mg on the first day of each treatment cycle, repeated every three weeks for up to one year or until disease progression or unacceptable side effects occur. The placebo arm follows the same schedule and administration method. Tumor response and minimal residual disease are monitored regularly using computed tomography or magnetic resonance imaging. Throughout the study, participants undergo tumor assessments every 12 weeks for the first two years, then every 24 weeks during the third year, and annually afterward until disease progression or death occurs. The study also measures overall survival, response rates, and disease control rates over up to 36 months. Participants health and response to treatment are closely monitored, and they are followed until disease progression or for the duration of the study period.
CONDITIONS
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
S
Shen Zhao, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year or until disease progression or intolerable toxicity
Participants receive intravenous infusion of either Sugemalimab or placebo every 3 weeks for up to 1 year, or until disease progression or intolerable toxicity.
Infusions every 3 weeks
Duration - Up to 3 years or until confirmed disease progression or death
Participants undergo tumor assessments and MRD detection every 12 weeks for the first 2 years, every 24 weeks for the third year, and annually thereafter until confirmed disease progression or death.
Visits every 12 weeks for 2 years, every 24 weeks for 1 year, then annually
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alyson Haslam, Vinay Prasad
https://pubmed.ncbi.nlm.nih.gov/31050774/Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal
https://pubmed.ncbi.nlm.nih.gov/31912902/Emmanuel Acheampong, Afaf Abed, Michael Morici...
https://pubmed.ncbi.nlm.nih.gov/33142852/Maria Coakley, Isaac Garcia-Murillas, Nicholas C Turner
https://pubmed.ncbi.nlm.nih.gov/31088829/Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal
https://pubmed.ncbi.nlm.nih.gov/29313949/J P Pignon, R Arriagada, D C Ihde...
https://pubmed.ncbi.nlm.nih.gov/1331787/Joaquim Bellmunt, Maha Hussain, Jürgen E Gschwend...
https://pubmed.ncbi.nlm.nih.gov/33721560/P Warde, D Payne
https://pubmed.ncbi.nlm.nih.gov/1316951/Shen Zhao, Kehui Chen, Xinyi Shi...
https://pubmed.ncbi.nlm.nih.gov/37442748/A T Turrisi, K Kim, R Blum...
https://pubmed.ncbi.nlm.nih.gov/9920950/Sun Yat-sen University
Lead Sponsor